
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP4F22 CRISPR/Cas9 KO Plasmid (h) | sc-414275 | 20 µg | $397.00 | |||
CYP4F22 HDR Plasmid (h) | sc-414275-HDR | 20 µg | $445.00 |
CYP4F22 encodes a cytochrome P450 monooxygenase that participates in lipid oxidation, with reported roles in the production and metabolism of specialized fatty acids that support epidermal barrier formation. In skin, CYP4F22 activity is linked to pathways governing ceramide-related lipid processing and terminal keratinocyte differentiation, which together influence stratum corneum integrity and transepidermal water loss. Genetic disruption of CYP4F22 has been associated with autosomal recessive congenital ichthyosis, highlighting its relevance to barrier dysfunction phenotypes and inflammatory signaling secondary to impaired epidermal lipid homeostasis. As a microsomal enzyme within the broader CYP4 family, CYP4F22 is also studied in the context of oxidative lipid networks and cross-talk with eicosanoid and fatty-acid signaling.
CYP4F22 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP4F22 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the CYP4F22 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, CYP4F22 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined CYP4F22 target site.
When co-transfected with CYP4F22 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the CYP4F22 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.